Patents by Inventor Mohammed Sharief
Mohammed Sharief has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120142775Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of ?-linolenic acid, dihomo-?-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-?1 levels in the patient to therapeutic levels.Type: ApplicationFiled: February 1, 2012Publication date: June 7, 2012Applicant: BTG International LimitedInventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief, Paul Barraclough
-
Publication number: 20110184063Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a triglyceride oil containing both ?-linolenic acid and linoleic acid residues as triglyceride ester, the ratio of ?-linolenic acid to linoleic acid residues at the sn-2 position of the triglyceride being at least 0.8; the amount of ?-linolenic acid residues at the sn-2 position being at least 18%, wherein the oil is administered at a dose sufficient to maintain or elevate TGF-?1 levels in the patient at a therapeutic level. Preferably the method is that wherein the therapeutic level is such as to produce a TGF-?1/TNF-? ratio of at least 0.5 in blood of a patient, after 18 months of daily dosing. Preferred oils are Borage or Mucor oils having at least 35% of the sn-2 position fatty acid residues as ?-linolenic acid.Type: ApplicationFiled: April 6, 2011Publication date: July 28, 2011Applicant: BTG International LimitedInventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief
-
Patent number: 7964641Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of ?-linolenic acid, dihomo-?-linolenic acid and arachidonic acid characterized in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-?1 levels in the patient to therapeutic levels.Type: GrantFiled: August 13, 2004Date of Patent: June 21, 2011Assignee: BTG International LimitedInventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief, Paul Barraclough
-
Patent number: 7935729Abstract: Method for treating a patient in need of therapy for a neurodegenerative disease by administering to that patient a therapeutically effective dose of a triglyceride oil containing both ?-linolenic acid and linolenic acid residues as triglyceride ester. The ratio of ?-linolenic acid to linolenic acid residues at the sn-2 position of the triglyceride is at least 0.8. The amount of ?-linolenic acid residues at the sn-2 position is at least 18%. The oil is administered at a dose sufficient to maintain or elevate TGF-?1 levels in the patient at a therapeutic level.Type: GrantFiled: May 14, 2004Date of Patent: May 3, 2011Assignee: BTG International LimitedInventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief
-
Publication number: 20100113595Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of ?-linolenic acid, dihomo-?-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-?1 levels in the patient to therapeutic levels.Type: ApplicationFiled: December 31, 2009Publication date: May 6, 2010Applicant: BTG International LimitedInventors: Lawrence S. Harbige, Michael J. Leach, Mohammed Sharief, Paul Barraclough
-
Publication number: 20100113810Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of ?-linolenic acid, dihomo-?-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-?1 levels in the patient to therapeutic levels.Type: ApplicationFiled: December 31, 2009Publication date: May 6, 2010Applicant: BTG International LimitedInventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief, Paul Barraclough
-
Publication number: 20090036410Abstract: A method of treating a patient in need of therapy for a disease in which cyokines have become dysregulated, or are otherwise capable of modulation to provide therapeutic benefit, is provided comprising administering to that patient a therapeutically effective dose of a phospholipid comprising a phosphatidyl group esterifed with one or more fatty acyl groups, characterised in that the phospholipid has at least one fatty acyl group at the sn-1 and/or sn-2 position of the phosphatidyl group, the fatty acyl group being selected from the group consisting of ?-linolenoyl, dihomo-?-linolenoyl acid and arachidonoyl.Type: ApplicationFiled: November 25, 2005Publication date: February 5, 2009Applicant: BTG INTERNATIONAL LIMITEDInventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief, Paul Barraclough
-
Publication number: 20080194684Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of ?-linolenic acid, dihomo-?-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-? levels in the patient to therapeutic levels.Type: ApplicationFiled: August 13, 2004Publication date: August 14, 2008Applicant: BTG International LimitedInventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief, Paul Barraclough
-
Publication number: 20080090908Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a triglyceride oil containing both ?-linolenic acid and linolenic acid residues as triglyceride ester, the ratio of ?-linolenic acid to linolenic acid residues at the sn-2 position of the triglyceride being at least 0.8; the amount of ?-linolenic acid residues at the sn-2 position being at least 18%, wherein the oil is administered at a dose sufficient to maintain or elevate TGF-?1 levels in the patient at a therapeutic level. Preferably the method is that wherein the therapeutic level is such as to produce a TGF-?1/TNF-? ratio of at least 0.5 in blood of a patient, after 18 months of daily dosing. Preferred oils are Borage or Mucor oils having at least 35% of the sn-2 position fatty acid residues as ?-linolenic acid.Type: ApplicationFiled: May 14, 2004Publication date: April 17, 2008Applicant: BTG INTERNATIONAL LIMITEDInventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief
-
Publication number: 20040229873Abstract: A method of treating a patient in need of therapy for multiple sclerosis is provided, comprising administering to that patient a therapeutically effective dose of a compound of formula I 1Type: ApplicationFiled: January 14, 2004Publication date: November 18, 2004Applicant: BTG International LimitedInventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief